Chromosome 17 News and Research

RSS

Humans normally have 46 chromosomes in each cell, divided into 23 pairs. Two copies of chromosome 17, one copy inherited from each parent, form one of the pairs. Chromosome 17 spans about 79 million base pairs (the building blocks of DNA) and represents between 2.5 percent and 3 percent of the total DNA in cells.

Identifying genes on each chromosome is an active area of genetic research. Because researchers use different approaches to predict the number of genes on each chromosome, the estimated number of genes varies. Chromosome 17 likely contains between 1,200 and 1,500 genes.

Genes on chromosome 17 are among the estimated 20,000 to 25,000 total genes in the human genome.

Genomic analysis of neuroblastoma sheds light on childhood solid tumors

Researchers have used insight from a comprehensive genomic analysis of neuroblastoma to learn about the process driving one of the most common childhood solid tumors. The findings revealed possible approaches for developing precision medicines to improve patient outcomes. St. Jude Children's Research Hospital scientists led the study, which appears today in the journal Nature Communications.

15 Oct 2020

Study uncovers genetic vulnerability in breast cancers tumors

The study, published in the scientific journal Nature, has uncovered a genetic vulnerability present in nearly 10% percent of all breast cancers tumours, and found a way to target this vulnerability and selectively kill cancer cells.

9 Sep 2020

Daily alcohol consumption ages brain

There are several studies looking at the effects of alcohol intake on the brain. Anew study adds to the existing knowledge. The large study with around 11,651 participants from United Kingdom shows that each gram of alcohol consumed could lead to around a week of aging of the brain.

2 Feb 2020

Unexpected connection found between feeding and memory centers of the brain

The search for a mechanism that could explain how the protein complex NCOR1/2 regulates memory has revealed an unexpected connection between the lateral hypothalamus and the hippocampus, the feeding and the memory centers of the brain, respectively.

21 Jan 2019

Study highlights opposite effects of gene following different types of environmental events

Researchers have discovered that the same gene which increases your risk of depression following financial stress as you grow older also reduces your chance of depression associated with friendship and relationships stresses when young- your social network.

8 Oct 2018

Scientists explore interactions between chromosomes 12 and 17

How are chromosomes arranged in the cell nucleus? Is it possible that they communicate with one another by "touching" each other?

21 Jun 2018

Genomic roots of ovarian tumors may arise in fallopian tubes, study suggests

Some scientists have suspected that the most common form of ovarian cancer may originate in the fallopian tubes, the thin fibrous tunnels that connect the ovaries to the uterus.

24 Oct 2017

Scientists use brain organoids to identify root causes of Miller-Dieker syndrome

Research led by scientists at UC San Francisco and Case Western Reserve University School of Medicine has used brain "organoids" — tiny 3D models of human organs that scientists grow in a dish to study disease — to identify root causes of Miller-Dieker Syndrome (MDS), a rare genetic disorder that causes fatal brain malformations.

7 Feb 2017

New study shows variation in junk DNA can affect health

All humans are 99.9 percent identical, genetically speaking. But that tiny 0.1 percent variation has big consequences, influencing the color of your eyes, the span of your hips, your risk of getting sick and in some ways even your earning potential.

30 Aug 2016

Kataegis linked to better prognosis for breast cancer patients

Kataegis is a recently discovered phenomenon in which multiple mutations cluster in a few hotspots in a genome. The anomaly was previously found in some cancers, but it has been unclear what role kataegis plays in tumor development and patient outcomes.

1 Jul 2016

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion.

17 May 2016

PERK inhibition can be a promising therapeutic strategy for neurodegenerative diseases

A major challenge in the field of neurodegeneration is the unclear understanding of neuronal dysfunction. Elucidation of these patho-mechanisms could result in the identification of novel therapeutic targets. In this article, Bell et al. present an exhaustive literature review highlighting the endoplasmic reticulum (ER) kinase PERK as a crucial contributor to systemic and neurodegenerative disorders.

20 Mar 2016

Researchers identify new mutation responsible for spinocerebellar ataxia

Using the genetic information of two different families with three generations of disease, researchers have identified a new mutation responsible for a degenerative and ultimately fatal movement disorder. Through induced pluripotent stem cell techniques, researchers also grew neurons from one patient in the laboratory to be used in future experiments.

15 Mar 2016

Specific environmental influences can neutralize effect of genetic variant that increases childhood asthma risk

The effect of a widespread genetic variant that increases the risk for childhood asthma can be neutralized. A new study shows that young infants are particularly responsive to the positive influence of exposure to farm dust.

27 Nov 2015

UK Biobank genetic study shows link between lung disease and smoking behaviour

New research published in The Lancet Respiratory Medicine and presented at this year's European Respiratory Society meeting in Amsterdam presents the first analyses of genetic data from the UK Biobank that reveal new associations with lung disease and smoking behaviour.

28 Sep 2015

$AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion$

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis.

12 Aug 2015

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.

12 Jul 2015

Study on how maternal proteins help regulate initial cell divisions during early development

Researchers in the University of Georgia's Regenerative Bioscience Center are visually capturing the first process of chromosome alignment and separation at the beginning of mouse development. The findings could lead to answers to questions concerning the mechanisms leading to birth defects and chromosome instability in cancer cells.

10 Jun 2015

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall survival (OS) and overall response rate (ORR) in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL, respectively) in the final analysis of the Phase III RESONATE™-2 (PCYC-1115) trial.

5 Jun 2015

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.

1 Jun 2015